As if I haven't posted on here repeatedly why leronlimab is superior to lenzilumab. We aren't kissing big pharma's ass and won't get notice until statistically significant data for a primary endpoint is released. That's the reality of the situation. If you've done so little due diligence you don't realize exactly where your stock is and prefer to constantly whine about it buy something else. It will save everyone else from having to listen to the stupidity.